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Aims.  To review evidence for novel drug targets that can manage overactive bladder 
symptoms.  Methods. A think tank considered evidence from the literature and their own 
research experience to propose new drug targets in the urinary bladder to characterise their 
use to treat overactive bladder. Results.  Five classes of agents or cellular pathways were 
considered. 1) Cyclic nucleotide-dependent (cAMP and cGMP) pathways that modulate ATP 
release from motor nerves and urothelium.  2) Novel targets for beta-3 agonists, including the 
bladder wall vasculature and muscularis mucosa.  3) Several TRP channels (TRPV1, TRPV4, TRPA1, 
TRPM4) and their modulators in affecting detrusor overactivity. 4) small conductance Ca2+-
activated K+ channels and their influence on spontaneous contractions. 5) antifibrosis agents 
that act to modulate directly or indirectly the TGF-beta pathway - the canonical fibrosis 
pathway. Conclusions. Specificity of action remains a consideration if particular classes of 
agents can be considered for future development as receptors or pathways that mediate 
actions of the above potential agents are distributed among most organ systems.  The tasks are 
to determine: more detail of the pathological changes that occur in the overactive bladder and; 
how specificity of potential drugs may be directed to bladder pathological changes.  An 
important conclusion was that the storage, not the voiding, phase in the micturition cycle 
should be investigated and potential targets lie in the whole range of tissue in the bladder wall 







This article is a summary of a Think Tank to identify potential novel targets to minimise 
symptoms of overactive bladder (OAB) and to suggest some research strategies to achieve this 
goal. Symptoms arising from primary neurological pathologies were beyond the scope of this 
discussion.  The current pharmaceutical options to manage OAB symptoms remain a triad of 
drug classes which are presumed to suppress directly detrusor contractions: anticholinergic 
agents; 3-receptor agonists; and pre-synaptic nerve-muscle blockers such as botulinum toxin.  
However, increasing evidence questions their predominant site of action as detrusor smooth 
muscle and in consequence this has stimulated the search for other drug targets on a range of 
cell types in the wall of the bladder.  The cause of OAB is probably multifactorial so that new 
drug candidates are continuously being explored1,2 and this discussion considered evidence for 
a range of different, potentially useful targets on the bladder wall including: detrusor muscle 
itself; excitatory motor nerves; the urothelium; the suburothelium and the extracellular space.   
 
Modulators of cyclic nucleotides and ATP release 
Cyclic nucleotides, such as cyclic AMP and cyclic GMP, are second messengers in a large range 
of biological processes so that intracellular pathways involving cyclic nucleotide turnover and 
signalling can be targeted to modulate their action. In particular, the effects of modulating cyclic 
nucleotide dependent pathways that mediate adenosine triphosphate (ATP) release from 
bladder wall tissues are of interest, as ATP is a functional neuromodulator in human OAB.  Thus, 
manipulation of ATP release through pathways regulated by cyclic nucleotides offers a route 
for therapeutic management of OAB.  
Adenylyl cyclase (AC) modulates the conversion of ATP to cAMP, and thus is a target for non-
selective activators of G-protein-coupled stimulatory pathways, via an action on the α subunit.  
For example, activation of β3-adrenoceptors utilises the prototypical transduction pathway for 
the Gs protein family, modulating AC activity and increasing the level of cAMP3. The β3-
adrenoceptor agonist, mirabegron, is used to treat OAB, and induces relaxes detrusor smooth 
muscle contractile activity via cAMP-dependent and -independent pathways4.  β3-
adrenoceptor agonists, BRL37344 and CL316243, reduce nerve-mediated contractions, with a 
greater effect on the atropine-resistant component of nerve-mediated contractions in 
 
 4 
comparison to the cholinergic component, and reduce P2X receptor-mediated contractions5. 
The AC activator, forskolin, also attenuates ATP-mediated responses; actions mirrored by 
activators of intermediates involved in downstream signalling of cAMP.  These include 6-MB-
cAMP (a protein kinase A (PKA) activator), and 007-AM the EPAC (Exchange Protein Activated 
by cAMP) EPAC activator.  This demonstrates that β3-adrenoceptor agonists reduce post-
junctional ATP-dependent responses in detrusor smooth muscle to a greater extent than 
acetylcholine-activated responses via cAMP-dependent pathways5.  
AC is also the target for the non-selective activators of the inhibitory G protein α subunit; for 
example, activation of adenosine A1 receptors utilises the prototypical transduction pathway 
for the Gi/Go protein family, inhibiting AC activity and decreasing cAMP levels3.  Adenosine 
reduces nerve-mediated contractions of human detrusor muscle more from patients with 
neuropathic detrusor overactivity (NDO) than those with stable bladders6.  In NDO detrusor 
samples, there is a greater effect at lower frequencies, i.e. where nerve-mediated contractions 
have a greater dependence on ATP release, compared to higher frequencies. These effects are 
mimicked by the adenosine A1 receptor agonist, N6-cyclopentyladenosine (CPA)6. The 
proposed mechanism of action in is that adenosine, metabolised from ATP at the 
neuromuscular junction via ectoATPases, acts at A1 receptors at the nerve terminal, resulting 
in inhibition of further neuronal ATP release from the efferent nerve.  This generates a self-
limiting response to excessive nerve-mediated ATP release6.  Reduction of ectoATPase activity 
would reduce this negative feedback and enhance purinergic contractions.  Adenosine also 
reduces distention-induced ATP release from rabbit urothelium or enhanced by the A1 receptor 
antagonist DPCPX or by adenosine deaminase, an enzyme that catalyses adenosine 
breakdown7.  Thus, adenosine, produced by ATP hydrolysis, has a negative feedback effect on 
ATP release from both efferent nerve terminals and the urothelium via A1 receptor activation.  
The nitric oxide (NO)-sensitive soluble guanylyl cyclase (sGC) converts guanosine triphosphate 
to cGMP3. sGC is the target of endogenous NO, and sGC activators and modulators, such as BAY 
41-2272 and BAY 60-2770, directly reduce bladder smooth muscle contractions8,9.  The sGC 
activator BAY 58-2667 reduces and ATP release and nerve-mediated contractions from efferent 
nerve terminals in isolated detrusor preparations [Chakrabarty B, Drake MJ, Kanai AJ, Fry CH, 
unpublished data].  
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Phosphodiesterases (PDEs) catalyse the hydrolysis of CNTs, with some subtypes expressing an 
affinity for cAMP and cGMP, whilst others have a greater affinity for cAMP or cGMP3.  PDE type- 
5 (PDE5) has a greater affinity for cGMP and sildenafil, a PDE5 inhibitor, elevates intracellular 
cGMP 3 and in humans alleviates LUTS10.  Sildenafil demonstrates a direct relaxant effect on 
human detrusor smooth muscle11. Moreover, it also attenuates nerve-mediated contractions, 
with a greater effect at the lower frequency, atropine-resistant, ATP-dependent component of 
nerve-mediated contractions12. Sildenafil also reduced nerve-mediated neuronal ATP release, 
and stretch-activated urothelial ATP release from isolated mucosal strips12.  
Targeting cyclic nucleotide-dependent pathways, or pathways involved in cyclic nucleotide 
turnover or signalling modulates the purinergic components of bladder contractions and 
urothelial ATP release. Targeting ATP release should attenuate pathological processes 
associated with enhanced ATP-dependent motor and sensory responses. 
Targets of β3-adrenoceptor agonists in the bladder? 
Nerve-mediated and spontaneous contractions.  Detrusor smooth muscle relaxation is proposed 
as a primary mechanism of β3-adrenoceptor agonists to improve bladder storage dysfunction. 
However, relatively high concentrations are required to relax pre-contracted isolated detrusor 
strips, with IC50 values of approximately 1μM13 and a similar potency is seen by reducing resting 
tone in human detrusor14. With mirabegron, currently the only clinically approved β3-
adrenoceptor agonist, the maximum plasma concentration of its therapeutic dose is lower than 
that required to relax isolated detrusor15.  However, direct attenuation of voiding contractions 
would be physiologically undesirable as this may cause urinary retention.  Thus, β3‐
adrenoceptor agonists could act at additional sites on the bladder wall.  The therapeutic effect 
of β3-adrenoceptor agonists is based on a widely-accepted role of sympathetic nerves during 
the storage phase; noradrenaline release from sympathetic nerves binds to detrusor muscle β3-
adrenoceptors to reduce its contractility.  However, sympathetic nerves to the bladder wall 
almost exclusively innervate blood vessels with very few fibers are distributed in the detrusor 
smooth muscle itself16.  Thus, whilst sympathetic, nerve-mediated β-adrenergic detrusor 
relaxation is difficult to detect, it is possible that direct application of β-adrenergic agonists 
relaxes detrusor via 'extra-junctional' receptors17.  
β3-adrenoceptor agonists also reduce acetylcholine (ACh) release or cholinergic nerve-
mediated detrusor contractions at clinically relevant concentrations18-20; through a direct action 
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on receptors expressed on cholinergic nerves, or via release of adenosine from detrusor that 
subsequently reduces cholinergic neurotransmission via A1 receptor activation19.  At present, 
different studies with human tissue show different β3-adrenoceptor expression patterns on 
detrusor muscle or cholinergic nerves; some with an emphasis of localization on detrusor, but 
not cholinergic nerve fibres (e.g.19), and others suggesting almost exclusive localization on 
cholinergic, adrenergic or sensory peptidergic fibres, but none on detrusor smooth muscle itself 
(e.g.20).  There may also be species differences of localisation and magnitude of expression as 
Western blot assays showed localisation of β3-adrenoceptor in human detrusor tissue but not 
in rat, that may in part be due to antibody affinity to the targets in rat and human tissue.  It is 
evident that more data are required to characterize β3-adrenoceptor location in bladder wall 
tissue from human and animals. 
Enhanced spontaneous detrusor phasic contractions, or bladder micromotions, during the 
storage phase are critical in urinary urgency21 and β3-adrenoceptors agonists may act more 
specifically to suppress aberrant spontaneous activity.  The relevance of an action on 
spontaneous contractions is that they, in turn, profoundly influence afferent firing from the 
bladder wall.  A mouse cystometric study showed that the magnitude and rate of change of 
spontaneous transient contractions had a 10-fold larger impact on afferent nerve firing 
compared with base-line changes22.  Thus, attenuation of aberrant spontaneous detrusor 
contractions or their rate of change - but not baseline tension - may be sufficient to improve 
bladder storage function. These findings reveal two important research questions regarding β3‐
adrenoceptor agonists: their relative potency to suppress spontaneous vs receptor-modulated 
contractions; and how they modulate spontaneous contractions. 
Both ACh and ATP are spontaneously released from nerves via TTX-insensitive mechanisms23,24. 
These may sum (in the case of ATP) to evoke excitatory junctional potentials and even detrusor 
action potentials. The role of β3-adrenoceptor agonists to attenuate spontaneous release of 
excitatory transmitters has not been explored. Because purinergic transmission is more evident 
in pathological human bladders, attenuation of ATP release may be more relevant. Moreover, 
β3-adrenoceptor agonists have more pronounced inhibitory effects on purinergic than 
cholinergic transmission5.      
The role of the mucosa. Bladder mucosa contains several cellular elements that could be a target 
for β3-adrenoceptor agonists including: urothelium, afferent nerves, interstitial cells and/or 
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fibroblasts, blood vessels and muscularis mucosae. As discussed above, attenuation of 
‘mechanosensitive’ afferent nerve firing by β3-adrenoceptor agonists may be a result of 
associated reduction of non-voiding spontaneous contractions.  Although non-voiding 
contractions may originate from detrusor, the bladder mucosa also has contractile properties, 
in several species including human25. A predominant contribution is from muscularis mucosae: 
it generates some ten-times more contractile strength compared to detrusor, when normalised 
to cross-section area, but only modestly responds to cholinergic stimulation26. Thus, it may be 
suggested that contraction of the muscularis mucosae is important in the storage phase, but 
not the voiding phase. Moreover, the close proximity of muscularis mucosae to afferent nerves 
offers another ‘mechanosensitive’ mode of afferent activation. The action of β3-adrenoceptor 
agonists on muscularis mucosae contraction is unknown but β3-adrenoceptor expressing 
nerves are abundantly distributed in the suburothelium20. It is of note that rat and mouse 
bladder lack a muscularis mucosae, and their mucosa is virtually non-contractile25. 
Effects on bladder wall blood vessels.  The vasculature of the bladder forms an extensive 
suburothelial capillary plexus so that the mucosa receives generous blood supply, at least during 
the storage phase27. Sympathetic nerves predominantly innervate bladder wall blood vessels 
and, in rat and mouse bladder, provide a functional innervation to suburothelial arterioles and 
venules28.  Neurally-released noradrenaline constricts venules via α-adrenoceptor activation, 
while causing vasodilatation via β-adrenoceptor stimulation. Thus, it may be proposed that β3-
adrenoceptors exert a therapeutic action by improving tissue perfusion25. In arterioles, 
mirabegron (100 nM) suppresses nerve-evoked Ca2+ transients by about 30% - a concentration 
similar to plasma levels (H Hashitani, unpublished data). Blood flow distribution within the 
bladder wall is regulated by the microvasculature, functioning as an integrated unit29.   Thus, 
the expression pattern of β3-adrenoceptors in different vascular segments and the response to 
β3-adrenoceptor agonists in regulating local and global blood flow should be explored.   
TRP channels 
Several channels of the TRP family have a role in nociception and mechanosensory transduction 
in the lower urinary tract (LUT).  A number of these channels, including TRPV1, TRPV4, TRPM8, 
TRPA1 and TRPM4, have been suggested from animal studies to be able to treat OAB/DO, 
bladder underactivity and bladder pain disorders30,31.  OAB is a filling, rather than a voiding, 
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disorder and demonstrates altered afferent signaling patterns.  This implies that modulation of 
pathways that determine bladder afferent activity can be effective therapies for OAB.  
TRPV1 channels. The function of TRPV1 channels in normal human bladder activity remains 
unclear. However, the therapeutic benefit in neurogenic DO (NDO) of agonists that desensitise 
TRPV1 channels (capsaicin, resiniferatoxin; when given intravesically) has been convincingly 
demonstrated. These agents are proposed to desensitise TRPV1 channels and so inactivate 
afferent neurons.   
Although there is no recent development of TRPV1 agonists to manage OAB/DO, animal 
experiments in different models of DO have suggested that blockade of TRPV1 receptors by 
small molecule compounds may have translational impact32. These agents have been developed 
for non-bladder problems and tested in human trials for safety but have not been used clinically 
to treat LUT dysfunction31.   The first generation of TRPV1 blockers have been associated with 
adverse effects such as hyperthermia and reduced sensation to noxious heat, and this has 
delayed development. However, despite these adverse effects, small molecule TRPV1 channel 
antagonists deserve consideration for translation to future drugs to manage LUT. 
TRPV4 channels. TRPV4 channels are present in urothelium and detrusor muscle cells and in 
urothelium are proposed to have important mechanosensory functions during bladder 
distension32.  With cystitis rodent models, induced by cyclophosphamide, HC-067047, the 
selective TRPV4 antagonist reduced the frequency of micturition and augmented functional 
bladder capacity32. With rats undergoing repeated external stresses, DO is induced by 
intravesical addition of TRPV4 agonists and improved by intravesical administration of HC-
067047.  These data suggest TRPV4 channels are a promising target for bladder overactivity 
disorders33. However, there are no current data about the effects of HC-067047 on human 
lower urinary tract dysfunction. 
TRPM8 channels.  TRPM8 channels are expressed in bladder mucosa and their abundance is 
positively associated voiding frequency in samples from patients with idiopathic DO.  This has 
led to the proposal that this channel subtype contributes to the pathophysiology of this 
disorder34.  In humans, treatment with a selective TRPM8 antagonist, PF-05105679, reduced 
significantly pain from a cold pressor test, but had no effect on core temperature35.  However, 
with two subjects in his study there was an intolerable sensation of perioral heat, an adverse 
effect that has precluded further tests 
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TRPA1 channels.  These channels sense noxious stimuli in animal and human bladder. They are 
expressed in some capsaicin-sensitive sensory afferents and react as polymodal sensors to a 
number of extracellular or intracellular physical and chemical stimuli31. TRPA1 channels have 
also been identified on urethral C-fibre afferents and urothelial cells as well as detrusor 
myocytes from human tissue.  Furthermore, intravesical application of TRPA1 channel activators 
initiate DO-like activity. Together it has been proposed that they have a role in modulating both 
efferent and afferent fibre activity in both the bladder and outflow tract31. There seems to be 
no information on the use of TRPA1 antagonists in OAB/DO treatment in humans, but TRPA1 
antagonists for alleviation pain has been tested in preliminary trials36. 
TRPM4 channels. These monovalent cation-selective channels are broadly expressed in several 
rodent and human tissues, including urothelium and detrusor.  Furthermore, they are 
upregulated in the urothelium and detrusor of mice after spinal cord transection37.  Blockade 
of TRPM4 channels in human detrusor myocytes with 9-phenanthrol reduced spontaneous 
inward current transients, associated with their hyperpolarisation and attenuation of 
spontaneous contractions in tissue strips38. These studies suggest TRPM4 channels but there are 
no published trials in humans.  
Several TRP channel subtypes are found in lower urinary tract tissues and a number of animal 
studies lend weight to the possibility that channel modulation may have therapeutic value to 
manage LUT functional disorders. However, there are caveats to this approach: animal models 
of LUT dysfunction can be unreliable; and the efficacy of channel modulators in humans is 
unclear. However, they remain interesting potential targets for future development. 
BK/SK K+ channels  
Over several decades, the physiological relevance of detrusor K+ channels in bladder physiology 
has been recognised as having the potential to be harnessed to treat DO.  A complement of K+ 
channels contribute to maintaining the resting membrane potential, as well as action potential 
repolarisation and after-hyperpolarization in detrusor smooth muscle cells39.  These include 
Ca2+-activated K+ channels with large or small unit ion conductance; BK and SK channels 
respectively.  The hypothesis that K+ channel openers, particularly BK channel openers, could 
be developed to limit detrusor smooth muscle excitability and therefore treat overactivity, has 
been tested in bladder tissue and cells from humans and small animals.   
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BK and SK channel blockers, iberiotoxin and apamin respectively, enhance spontaneous 
contractions in human bladder strips, demonstrating channel functionality under normal 
conditions40,41.  Patch-clamp electrophysiology has characterised pharmacological and 
biophysical properties of BK currents in human detrusor myocytes from normal bladders42. 
However, neither iberiotoxin nor a BK channel opener, affected spontaneous contractions in 
bladder tissue from neurogenic bladders42 and PCR experiments indicated significant 
downregulation of the BKα gene, KCNMA1, in neurogenic bladder41.  These reports are 
consistent with observations of bladder overactivity in mice lacking BK channels43.  It is 
therefore perhaps unsurprising that clinical trials of BK channel openers as putative drug 
treatments for detrusor overactivity have been unsuccessful44. The possibility of restoring BK 
expression in neurogenic human detrusor smooth muscle cells via gene therapy has been 
promising in pre-clinical in vivo studies45, has been trialled in human erectile dysfunction 
patients46 and is being explored in clinical trials with intravesical application of BK units47.  The 
results of these clinical trials on BK channel modulation in OAB patients have not yet been fully 
reported. 
The observation that blockade of SK channels enhanced spontaneous contractions in 
neurogenic bladder tissue42 suggests that SK channel openers could also be developed to treat 
bladder overactivity.  The SK channel opener SKA-31 decreased spontaneous contractions in 
normal human bladder detrusor strips48.  However, its additional reduction of nerve-evoked 
contractions also highlighted the fact that SK openers to treat overactive bladder may adversely 
impact voiding contractions leading to urinary retention. Further research is needed in this area. 
Anti-fibrosis strategies 
Bladder wall fibrosis and overactive bladder symptoms.  Many bladder pathologies that 
demonstrate OAB symptoms also shows replacement of detrusor smooth muscle with 
connective tissue (fibrosis) that consists of collagens and elastin embedded in a ground 
substance of proteoglycans49.  This apparently counter-intuitive observation may be explained 
in several ways: ECM is generally stiffer than muscle tissue so that bladder wall compliance is 
reduced, with sensory thresholds achieved at lower filling volumes; detrusor spontaneous 
contractions arise when nerve-mediated responses are suppressed50; and the increased density 
of collagen-producing cells, such as myofibroblasts and interstitial cells, themselves generate 
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irregular propagating electrical signals51.  Reduction of ECM deposition will therefore be a useful 
target to restore normal bladder function. 
TGF- and fibrosis.  TGF- is a polypeptide cytokine that belongs to a transforming growth 
factor superfamily including three mammalian isoforms, TGF-1 to - 3.  They are released by 
many cells in an inactive form, but when activated by several extracellular proteinases they bind 
to receptors (TGFR1,2) that initiate intracellular signalling pathways leading to fibrosis52.  A 
canonical pathway consists of: phosphorylation of associated Smad proteins (Smad2 and 
Smad3) and binding to Smad4; Smad3 binding to gene promoters that induce transcription of 
fibrosis products, tissue inhibitor of matrix metalloproteinase (MMP) and transformation of 
fibroblasts and epithelial cells to collagen-producing myofibroblasts.  In this pathway Smad2 
and Smad4 act as regulators of Smad3.  TGFR-Smad signalling can in turn interact with other 
potentially fibrosis-inducing pathways including Wnt/-catenin, that is present at least in the 
neonatal bladder53.   
Modulation of the of TGF- pathway. Attenuation of the above pathway should in principle 
reduce fibrosis and two examples will exemplify this approach.  Bone morphogenic protein-7 
(BMP-7) is part of the TGF- superfamily that on binding to its receptor also induces 
phosphorylation of Smad proteins – Smad1,5,8.  These require the same chaperone, Smad4, to 
translocate to the nucleus, in this case to initiate anti-fibrotic pathways.  Thus, not only will this 
pathway be initiated by BMP-7 but its sequestration of Smad4 will also reduce the fibrotic TGF-
 pathway. Proof-of-principle has been demonstrated in several tissues, including liver and 
kidney54, although there are no data regarding bladder fibrosis.   
Peroxisome proliferator-activated receptors (PPAR) are nuclear transcription factors with 
antifibrotic effects.  There are three known subtypes (  and ) and PPAR has received most 
attention as it is the target for oral antidiabetic drugs, thiazolidinediones.  The antifibrotic 
effects of PPAR agonists on many tissues has long been known and is largely through inhibition 
of the TGF- pathway, or the Wnt pathway, at a number of sites55. However, experience with 
bladder fibrosis is lacking and as with BMP-7 these offer potential antifibrotic strategies to be 
pursued. 
Antifibrotic actions of relaxin and cGMP.  The insulin superfamily in humans consists of insulin, 
insulin-like growth factors and three relaxin subtypes (H1-3) and several insulin-like peptides.  
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Relaxin peptides are agonists for relaxin family peptide (RXFP) G-protein coupled receptors, 
with the most studied interaction between H2 and RXFP156.  Antifibrotic actions have been 
recorded in the lung, kidney, liver, portal vein and heart, which has been translated into 
successful clinical trials, as well as in rat bladder subjected to X-ray irradiation57.  With the rat 
bladder, cystometry showed reversal of a phenotype showing a low compliance, overflow 
incontinence pattern with spontaneous contractions to a normal high compliance bladder with 
transient voiding contractions.  The return of voiding contractions was mirrored by enhanced 
in vitro detrusor contractions and enhanced expression of L-type Ca2+ channel units 
demonstrating a multi-faceted action of relaxin, as observed in other organs such as the 
kidney58.  The antifibrotic action of relaxin, in part, is through modulation of the TGF- pathway.  
RXFP1 activation by H2 eventually increases intracellular cGMP, via ERK1 phosphorylation, nitric 
oxide synthase activation and NO-dependent soluble guanylate cyclase (sGC)activation59: cGMP 
itself prevents phosphorylation of the Smad2,3 complex. 
More immediate ways to increase intracellular cGMP are through attenuation of its breakdown 
through inhibition of phosphodiesterase5 (PDE5) or direct action of sGC.  PDE5 inhibitors, 
including, sildenafil and tadalafil have been extensively investigated in the genito-urinary tract 
as direct or indirect smooth muscle relaxants.  Several sGC activators, such as riociguat and 
cinaciguat, have also been developed initially to minimise cardiovascular problems.  The 
potential usefulness of PDE5 inhibitors to reduce fibrosis in the genito-urinary tract has been 
proposed60 with initial studies in prostate and corpus cavernosal tissue have been.  However, 
to our knowledge no systematic investigations have targeted the bladder.  Similarly, sGC 
activators have anti-fibrotic actions in many experimental models of renal and cardiovascular 
diseases61 and direct application to the bladder is awaited. 
Other targets 
This review has summarised the discussion held at ICI-RS 2019 and so is not comprehensive of 
new advances that have identified potential drug targets to mitigate the effects of OAB.  
However, it is important to recognise additional advances made in identifying LUT-selective 
targets, for example in areas of purinergic signalling and modulation of other K+ channels. OAB 
is associated with increased efferent nerve and urothelial purinergic signalling with one 
potential target at P2X3 receptors on afferent nerves.  The P2X3 receptor antagonist AF-219 has 
been shown to attenuate afferent signalling: it is currently under clinical trials for chronic cough 
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syndromes62, proposed for hypertension63 and reported for bladder pain syndrome64. An 
increase of the conductance of K+ channels is also an attractive target to reduce overactive 
bladder contraction. However, a major obstacle is an off-target effect of relaxing vascular 
smooth muscle and so generating hypotension. Recent advances that bladder-specific isoforms 
of Kv7 channels may be identified and their further development is awaited with interest65,66. 
 
Conclusion 
OAB medications can be administered intravesically, but the value of alternative oral drugs is 
clearly preferable. However, the presence of targets in the bladder may well be matched by 
expression in other crucial organ systems, such as the cardiovascular and neurological systems, 
and thus far has limited development of oral compounds that affect TRP and K+ channels. 
Antimuscarinic medications are accepted as the severity of their systemic influences is often 
manageable and 3 agonists and PDE5 inhibitors have a low chance of substantial systemic 
adverse effects. Thus, deeper insight into their mechanisms of action is valuable for two 
reasons: firstly, understanding how they work will help optimise their use (e.g. is there a 
particular phenotype of presentation that would predict a good response); secondly, drugs 
targeting downstream elements of intracellular pathways could be more efficacious.  For 
example, soluble GC activators are interesting as this enzyme is a downstream target of PDE5 
inhibitors. Moreover, recent work has recognised that modulation of the storage phase, rather 
than the voiding phase, is important to manage OAB symptoms, even with current agents.  In 
this context there should be a greater emphasis on future research describing how current and 
potentially useful agents have direct or indirect actions of afferent nerve activity.  Furthermore, 
how such information is processed in the central nervous system will also be crucial to 
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